While commercial blood companies, sensitive to the demands of hemophiliacs, supported testing, nonprofit blood banks, most notably the American Red Cross, continued to oppose it. As usual, the blood bankers argued cost, saying that testing would add $12 to the cost of a unit of blood and that they would have to recruit new donors to replace the 6 percent of donors whose blood would be rejected because of the testing.
